When should radiation therapy be initiated for a patient with a portal vein tumor thrombus (vp4) after a subcapsular hepatic bleed, assuming the bleed is stable, liver function is Child‑Pugh A or B, and the patient is receiving systemic therapy with atezolizumab (1200 mg IV every 3 weeks) and lenvatinib (12 mg orally daily, or 8 mg if body weight < 60 kg)?

Radiation Therapy for VP4 Tumors: Timing After Subcapsular Hepatic Bleed

For patients with VP4 portal vein tumor thrombus and a stable subcapsular hepatic bleed on atezolizumab-lenvatinib therapy, radiation therapy should be initiated once the bleed is confirmed stable (typically 1-2 weeks after bleeding cessation) and liver function remains Child-Pugh A or B7, as external beam radiation therapy (EBRT) can be safely combined with systemic therapy and provides critical local control for this high-risk population.

Clinical Context and Rationale

VP4 portal vein tumor thrombus represents main portal vein invasion—the most advanced form of vascular involvement in hepatocellular carcinoma. This carries a dismal prognosis with median survival of only 2-4 months without treatment 1, 2. The combination of systemic therapy with local control via radiation is increasingly recognized as beneficial for this population.

Guideline-Based Recommendations for EBRT in VP4 Disease

When to Use Radiation

The 2022 Korean guidelines explicitly state that EBRT can be performed for treatment of HCC with portal vein invasion (B2 evidence) and that EBRT can be combined with systemic therapy for HCC treatment (C2 evidence) 3. The British Society of Gastroenterology 2024 guidelines similarly support stereotactic radiotherapy as an option for tumors not suitable for other techniques 4.

Prerequisites for Safe Radiation Delivery

According to the 2022 Korean guidelines, EBRT should only be performed when 3:

• Liver function is Child-Pugh grade A or B7 (B1 evidence)
• The volume to be irradiated with ≤30 Gy is ≥40% of the total liver volume in the computerized treatment plan (B1 evidence)

Your patient meets these criteria with Child-Pugh A or B liver function.

Timing Considerations After Subcapsular Bleed

Stability Assessment

While guidelines don't specify exact timing post-hemorrhage, clinical practice dictates:

1. Confirm hemodynamic stability: No ongoing bleeding, stable hemoglobin, no need for transfusion
2. Imaging confirmation: Follow-up CT or MRI showing stable or resolving hematoma (typically 7-14 days after initial bleed)
3. Liver function preservation: Ensure Child-Pugh score remains A or B7

Rationale for Early Initiation

Rapid progression is the enemy in VP4 disease. Untreated VP4 tumor thrombus leads to:

• Progressive portal vein obstruction
• Hepatic decompensation
• Intrahepatic and distant metastasis 1
• Median survival of only 2-4 months 1, 2

Recent data shows that concurrent radiation with immunotherapy in VP4 patients achieves median overall survival of 7.7 months overall, but 10.2 months in Child-Pugh A patients 5. This represents a substantial improvement over historical controls.

Radiation Technique and Dosing

Dose-Response Relationship

A Western cohort study demonstrated that biologically effective dose (BED) >75 Gy significantly improves outcomes in HCC with portal vein tumor thrombus 6:

• Local control at 1 year: 93.3% vs 45.6% (BED >75 Gy vs ≤75 Gy, p=0.0184)
• Median survival: 24.7 months vs 6.1 months (p=0.002)
• 1-year overall survival: 76.5% vs 30.0%

Treatment Options

Stereotactic body radiotherapy (SBRT) is preferred when feasible:

• Delivers ablative doses in fewer fractions
• Achieves 40-60% objective response rates 1
• Shows complete response in 16.1%, partial response in 41.9% of VP4 cases 7
• Minimal risk of radiation-induced liver disease when properly planned 7

Conventional fractionated EBRT is used when:

• Tumor volume too large for SBRT
• Proximity to critical structures limits SBRT dose
• Patient cannot tolerate short immobilization times

Integration with Systemic Therapy

Continuation of Atezolizumab-Lenvatinib

Do not interrupt systemic therapy for radiation. The 2022 Korean guidelines explicitly state EBRT can be combined with systemic therapy (C2 evidence) 3. Recent evidence supports this approach:

• A 2025 study of concurrent radiation and immunotherapy in VP4 patients showed this combination is feasible and potentially synergistic 5
• No significant increase in toxicity when combining EBRT with immunotherapy
• Median overall survival of 10.2 months in Child-Pugh A patients receiving combined therapy 5

Lenvatinib Dosing Considerations

Your patient is already on appropriate weight-based dosing 8:

• 12 mg daily for patients ≥60 kg
• 8 mg daily for patients <60 kg

Continue this dosing through radiation unless toxicity requires adjustment. The FDA label confirms lenvatinib pharmacokinetics are not significantly altered by concurrent therapies 8.

Monitoring During Combined Therapy

Liver Function Surveillance

Critical monitoring parameters:

• Child-Pugh score every 2-4 weeks during treatment
• If progression to Child-Pugh B8 or higher, consider radiation interruption
• Monitor for ascites development (contraindication to further TACE but not necessarily EBRT)

Treatment-Related Toxicity

Common grade 3-4 adverse events with lenvatinib in HCC patients 8:

• Hypertension (23%)
• Decreased appetite (5%)
• Fatigue (4%)
• Palmar-plantar erythrodysesthesia (3%)

When combining with radiation, monitor for:

• Radiation-induced liver disease (rare with modern planning)
• Additive fatigue
• Gastrointestinal toxicity (diarrhea, nausea)

Alternative Scenarios

If Child-Pugh Score Deteriorates to B8-B9

The 2022 Korean guidelines state sorafenib can be considered for Child-Pugh B8-9 (B2 evidence) 3, but atezolizumab-bevacizumab is only approved for Child-Pugh A 4. In this scenario:

• Consider switching to sorafenib or lenvatinib monotherapy
• EBRT may still be feasible if liver volume constraints can be met
• Focus shifts to palliative intent

If Bleed Recurs or Remains Unstable

• Delay radiation until stability confirmed
• Consider alternative local control: hepatic arterial infusion chemotherapy (HAIC) has shown promise in VP4 disease with Child-Pugh B function 9, 10
• Continue systemic therapy if tolerated

Common Pitfalls to Avoid

1. Waiting too long: VP4 disease progresses rapidly; don't delay radiation beyond 2-3 weeks post-bleed stabilization
2. Stopping systemic therapy: Radiation and immunotherapy/TKI are synergistic, not antagonistic
3. Inadequate dose: Target BED >75 Gy when feasible for optimal local control 6
4. Ignoring liver function: Child-Pugh B8 or higher significantly worsens outcomes 5
5. Overlooking radiation planning constraints: Ensure adequate liver volume sparing to prevent radiation-induced liver disease

Practical Algorithm

For your patient with stable subcapsular bleed, VP4 thrombus, Child-Pugh A/B, on atezolizumab-lenvatinib:

1. Week 1-2 post-bleed: Confirm stability with imaging, check hemoglobin, assess Child-Pugh score
2. Week 2-3: If stable, initiate radiation planning CT, continue systemic therapy
3. Week 3-4: Begin SBRT (preferred) or fractionated EBRT, target BED >75 Gy
4. Throughout treatment: Continue atezolizumab-lenvatinib without interruption
5. Every 2-4 weeks: Monitor Child-Pugh score, liver function tests, treatment toxicity
6. Post-radiation: Continue systemic therapy, reassess response at 4-6 weeks

3, 5, 6